Actively Recruiting
Molecular Residual Disease Study in Selected Solid Tumors Collecting Clinical Data and Biospecimens
Led by Paradigm Health · Updated on 2026-09-24
1350
Participants Needed
47
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are collecting clinical data and biological samples from adults diagnosed with stage I, stage II, or operable stage III cancers in certain solid tumor types. This observational study aims to help develop tests that improve cancer detection and assess the risk of cancer returning. Participants continue to receive standard care from their own doctors throughout the study. Participants will provide blood and tumor tissue samples during their routine care. The study includes several tumor groups such as bladder cancer, esophageal cancer, gastric and gastroesophageal junction cancer, melanoma, non-small cell lung cancer, pancreatic cancer, and a mix of other solid tumors. Enrollment occurs either before or within three months after surgery, and no prior systemic therapy for the current cancer is allowed before joining. During the approximately five and a half years of involvement, participants will be observed with collection of blood and tissue samples as part of a biospecimen registry. Researchers will use this information to study molecular residual disease in solid tumors. All clinical data and samples will be gathered under routine care settings, with no additional treatment provided by the study team.
CONDITIONS
Brief Title
Pan-tumor MRD Study
Research Team
A
Anosheh Afghahi, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here